Humble+ Cannabis Solutions signs 2-year agreement to serve as exclusive sales representation for Wyld in Canada

 Humble & Fume Inc. (CNSX: HMBL), a leading North American distributor of cannabis and cannabis accessories, announced today that its subsidiary Humble+ Cannabis Solutions (“HCS”) has entered into an exclusive sales representation agreement with Galaxie Brands Corporation (“Galaxie”), a subsidiary of The Green Organic Dutchman Holdings Ltd. (“TGOD”) for the commercialization and distribution of Wyld cannabis edibles in Canada.

The cannabis stock sector is booming, with legalization and decriminalization of marijuana in the United States and abroad rapidly expanding. In hot pursuit is the psychedelics industry, with legalization efforts initiated worldwide for a variety of different alternative medical treatments from this category. Investors want to know more about the cannabis and psychedelic investment opportunities from industry-leading experts. Today, we chatted with Alexej Pikovsky is the CEO and Founder of the Alphagreen Group. Alphagreen Group is a next-gen technology provider and e-commerce platform in the alternative health and wellness sector. The group began by launching alternative health and CBD marketplace alphagreen.io as the United Kingdom's CBD industry experienced speedy growth in 2020.

Gaia Grow Corp. (the “Company” or “Gaia”) (CSE:GAIA) (CNSX:GAIA.CN) (Frankfurt:GG0) is excited to announce that its wholly-owned subsidiary, TruExtracts Laboratories (“TRU”), has signed a 12-month white labeling agreement with an arms-length Canadian cannabis producer (“the producer”) to manufacture approximately 30,000 Cannabis pre-rolls per day. Production is expected to commence at TRU’s Canadian licenced Cannabis extraction facility in January of 2022. This agreement has the option to extend in 1-year increments beyond this term.

A small industry player outperforms its larger peers in 2021 and is the logical investment choice before the cannabis revolution happens.

Canada often has little choice but to bend to the heftier market forces of its neighbor to the south. The cannabis business was an exception after Ottawa legalized weed in 2018 and gave Canadian companies a lead. They've been angling for a stake in the larger U.S. market. But they need to act soon to make the most of the remaining early legalization buzz.

There were about $2 billion in cannabis sales in Canada in 2020, according to Bernstein analysts. That pales beside $17.5 billion in legal sales in the United States, where pot remains illegal at the federal level. Even without a change in that situation, Bernstein expects the American market will be worth some $40 billion a year by 2026.

Best Canadian Cannabis Stocks To Close 2021

Are you looking for top marijuana stocks to watch for 2022? In December most of the best cannabis stocks to invest in have declined to the lowest price points seen this year. As we head into 2022 the cannabis sector has sustained declines that could be an opportunity for new cannabis investors in 2022. One area that has been hit hard by the delays with federal cannabis reform is Canadian marijuana stocks.

Organigram Holdings Inc. OGI, 0.00% OGI, -0.44% said Tuesday it acquired all of the issued and outstanding shares of Laurentian Organic Inc. for about $28 million plus additional earnout considerations based on 2022 and 2023 Ebitda benchmarks. The Laurentian acquisition will allow Organigram to reach into premium products, including hash and craft cannabis, and grow its footprint in Quebec, the company said. Shares of Organigram rose 1% in premarket trades.

Licensing deal set to assist in the advancement of research and development for cannabinoid biosynthesis

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora"), the Canadian company defining the future of cannabinoids worldwide, together with 22nd Century Group, Inc. (NASDAQ: XXII) ("22nd Century") announced today a three-way non-exclusive agreement to license biosynthesis intellectual property to Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group"), intended to assist in the advancement of research and development on the biosynthesis of cannabinoids.

This popular Canadian pot company might be inviting trouble.

As with any evolving industry, the marijuana industry also suffers from volatility. The Canadian industry, in particular, has faced several headwinds since it legalized medical and recreational cannabis. However, amid all the challenges, a few of the cannabis players, like Canopy Growth (NASDAQ:CGC) and Aurora Cannabis (NASDAQ:ACB), stood out as the dominant players.